Docetaxel

Generic name
Docetaxel
Brand name
ATC Code
L01CD02
Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

The following kinetic parameters have been observed [Clarke 1999]:
Cl: 33.2 l/h/m²
V: 37 l/m²

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Ewing sarcoma, osteosarcoma and other recurrent/refractory solid tumours
  • Intravenous
    • 1 year up to 18 years

      • The dosage and dosing frequency of oncological agents depend on the condition and are very much subject to new insights. Oncological drugs are often used in combinations. For this reason, please refer to the detailed treatment protocols (see www.skion.nl)

        The following indicative dosages have been stated in the literature:
        - 100 mg/m²/dose every 3 weeks.

      • Treatment by or after consultations with a paediatric specialist (oncology) who has experience using docetaxel for this indication.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

The solvent in Taxotere contains ethanol.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Vinca alkaloids and analogues
L01CA01
L01CA02
Podophyllotoxin derivatives
L01CB01
L01CB02
Topoisomerase 1 (TOP1) inhibitors
L01CE02

References

  1. Clarke SJ et al., Clinical pharmacokinetics of docetaxel., Clin Pharmacokinet., 1999, Feb;36(2):, 99-114
  2. Aventis Pharma S.A.. , Taxotere: EPAR - Product Information (14-8-2015). , www.ema.europa.eu
  3. Mora J et al. , Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. , J Pediatr Hematol Oncol., 2009, Oct;31(10):, 723-9
  4. Yoon JH et al. , A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors. , BMC Cancer., 2014, Aug 28;14:, 622
  5. Navid F et al., Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma, Cancer., 2008, Jul 15;113(2), 419-25
  6. Song BS et al., Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience., Pediatr Blood Cancer., 2014, Aug;61(8):, 1376-81
  7. Aventis Pharma S.A.., Taxotere: EPAR - Product Information (14-8-2015)., www.ema.europa.eu
  8. Mora J et al., Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel., J Pediatr Hematol Oncol., 2009, Oct;31(10):, 723-9
  9. Yoon JH et al., A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors., BMC Cancer., 2014, Aug 28;14:, 622

Changes

Therapeutic Drug Monitoring


Overdose